期刊
AUTOIMMUNITY REVIEWS
卷 18, 期 7, 页码 665-672出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.autrev.2019.05.003
关键词
B cell; Multiple sclerosis; Monoclonal antibodies; CD20-target therapy
类别
资金
- 'Ricerca Corrente' 2017-2019 Grant [RC1812C]
Multiple sclerosis (MS) is an acquired demyelinating disease of the central nervous system (CNS) that traditionally has been considered to be mediated primarily by T cells. Increasing evidence, however, suggests the fundamental role of B cells in the pathogenesis and development of the disease. Recently, anti-CD20 B cell-based therapies have demonstrated impressive and somewhat surprising results in MS, showing profound anti-inflammatory effects with a favorable risk-benefit ratio. Moreover, for the first time in the MS therapeutic scenario, the anti-CD20 monoclonal antibody ocrelizumab has been granted for the treatment of the primary progressive form of the disease. In this review, we provide a brief overview about anti-CD20 B cell-based therapies in MS, in the perspective of their influence on the future management of the disease, and of their possible positioning in a new wider therapeutic scenario.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据